Loading the session
Loading the session
Loading instrument
$3.93
+0.00%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:32 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +5.9% (SPY −1.6%, XLV +13.5%). 3 months: −4.1% (SPY −0.4%, XLV +15.5%). 1 year: −28.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: MNKD, SPY and XLV · as of 4 Nov 2026
The 4 Nov 2026 close of $3.93 was 10.3% above its 50-day average ($3.56) and 6.1% above its 200-day average ($3.70). It has closed above the 200-day for 2 sessions, since 3 Nov 2026. The 50-day average crossed below the 200-day on 18 Mar 2026, 160 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
25.5M shares were sold short at the 15 Oct 2026 settlement, 7.9% of the 321.5M shares outstanding; covering them would take 5.1 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
Closed at $3.93 on 4 Nov 2026: 39.6% below the 52-week high of $6.51 (8 Jan 2026) and 76.2% above the low of $2.23 (27 Mar 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
MannKind Corp is a biopharmaceutical company dedicated to transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
May 6, 2026
+24.48%February 25, 2026
−36.82%September 2, 2025
+25.05%